JP2007529530A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007529530A5 JP2007529530A5 JP2007503993A JP2007503993A JP2007529530A5 JP 2007529530 A5 JP2007529530 A5 JP 2007529530A5 JP 2007503993 A JP2007503993 A JP 2007503993A JP 2007503993 A JP2007503993 A JP 2007503993A JP 2007529530 A5 JP2007529530 A5 JP 2007529530A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- group
- unsubstituted
- alkylene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 63
- 125000003118 aryl group Chemical group 0.000 claims description 40
- 150000001875 compounds Chemical class 0.000 claims description 40
- 125000002947 alkylene group Chemical group 0.000 claims description 32
- 125000001151 peptidyl group Chemical group 0.000 claims description 31
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 29
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 11
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 125000000524 functional group Chemical group 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 5
- 125000003277 amino group Chemical group 0.000 claims description 5
- 150000001721 carbon Chemical group 0.000 claims description 5
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 5
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 7
- 239000007795 chemical reaction product Substances 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims 1
- 150000003934 aromatic aldehydes Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 230000001590 oxidative effect Effects 0.000 claims 1
- 150000003462 sulfoxides Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 230000002062 proliferating effect Effects 0.000 description 6
- -1 2,4-dimethoxybenzyl Chemical group 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 2
- 206010038934 Retinopathy proliferative Diseases 0.000 description 2
- 206010068348 X-linked lymphoproliferative syndrome Diseases 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- 0 *C(*CC(OO)=O)c1cc(*O)ccc1 Chemical compound *C(*CC(OO)=O)c1cc(*O)ccc1 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 101000650863 Homo sapiens SH2 domain-containing protein 1A Proteins 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 102100027720 SH2 domain-containing protein 1A Human genes 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000033779 X-linked lymphoproliferative disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000011803 breast fibrocystic disease Diseases 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000035803 proliferative type breast fibrocystic change Diseases 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55400804P | 2004-03-16 | 2004-03-16 | |
| US60/554,008 | 2004-03-16 | ||
| PCT/US2005/008429 WO2005089269A2 (en) | 2004-03-16 | 2005-03-15 | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007529530A JP2007529530A (ja) | 2007-10-25 |
| JP2007529530A5 true JP2007529530A5 (enExample) | 2008-05-08 |
| JP4918476B2 JP4918476B2 (ja) | 2012-04-18 |
Family
ID=34994233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007503993A Expired - Fee Related JP4918476B2 (ja) | 2004-03-16 | 2005-03-15 | 増殖性疾患を治療するための置換フェノキシ−及びフェニルチオ−誘導体 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7932242B2 (enExample) |
| EP (2) | EP3138832A1 (enExample) |
| JP (1) | JP4918476B2 (enExample) |
| KR (1) | KR101274524B1 (enExample) |
| AU (2) | AU2005222947B2 (enExample) |
| CA (1) | CA2559187C (enExample) |
| DK (1) | DK1740530T3 (enExample) |
| EA (2) | EA200901236A1 (enExample) |
| ES (1) | ES2609084T3 (enExample) |
| HU (1) | HUE030786T2 (enExample) |
| IL (1) | IL176836A (enExample) |
| NZ (1) | NZ549962A (enExample) |
| WO (1) | WO2005089269A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004289281C1 (en) * | 2003-11-14 | 2011-12-08 | Onconova Therapeutics, Inc. | Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders |
| WO2006074149A2 (en) * | 2005-01-05 | 2006-07-13 | Temple University-Of The Commonwealth System Of Higher Education | Treatment of drug-resistant proliferative disorders |
| WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| CA2663375A1 (en) | 2006-09-15 | 2008-03-20 | Onconova Therapeutics, Inc. | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions |
| NZ621196A (en) * | 2008-01-22 | 2015-08-28 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| WO2010075026A2 (en) * | 2008-12-16 | 2010-07-01 | Onconova Therapeutics Inc | Methods for determining efficacy of a therapeutic regimen against deleterious effects of cytotoxic agents in human |
| US8735620B2 (en) | 2008-12-17 | 2014-05-27 | Epr Pharmaceuticals Pvt. Ltd | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders |
| WO2013056079A1 (en) * | 2011-10-13 | 2013-04-18 | The Johns Hopkins University | High affinity beta lactamase inhibitors |
| WO2014047110A2 (en) | 2012-09-20 | 2014-03-27 | Temple University - Of The Commonwealth System Of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
| US9655910B2 (en) | 2014-03-21 | 2017-05-23 | Bodybio Inc. | Compositions and methods for treating addiction |
| US10052339B2 (en) | 2014-03-21 | 2018-08-21 | Bodybio Inc. | Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids |
| WO2017023912A1 (en) | 2015-08-03 | 2017-02-09 | Temple University - Of The Commonwealth System Of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
| MX2022000938A (es) * | 2017-03-15 | 2022-12-14 | Lunella Biotech Inc | Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas. |
| CN112694499B (zh) * | 2020-12-14 | 2023-09-19 | 上海科技大学 | 一种交联剂及其制备与在质谱交联技术中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3865867A (en) * | 1967-06-19 | 1975-02-11 | Monsanto Co | Meta-bifunctional benzenes |
| US3975435A (en) * | 1974-03-06 | 1976-08-17 | Givaudan Corporation | Substituted cinnamanilides |
| JPS5720942B2 (enExample) * | 1974-04-18 | 1982-05-04 | ||
| JPS51126127A (en) * | 1975-03-11 | 1976-11-04 | Ricoh Co Ltd | Coupling component for diazotype photosensitive materials |
| ES8504461A1 (es) | 1982-04-12 | 1985-04-16 | Hybritech Inc | Un procedimiento para obtener un polidoma. |
| FR2559646B1 (fr) * | 1984-02-21 | 1986-07-18 | Centre Nat Rech Scient | Procede de reduction du taux de lignine dans les vegetaux et nouvelles compositions pour sa mise en oeuvre |
| US5169939A (en) | 1985-05-21 | 1992-12-08 | Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College | Chimeric antibodies |
| CA1282069C (en) | 1985-09-12 | 1991-03-26 | Damon L. Meyer | Antibody complexes of hapten-modified diagnostic or therapeutic agents |
| DD261149A5 (de) * | 1985-12-23 | 1988-10-19 | Ciba-Geigy Ag,Ch | Verfahren zur herstellung neuartiger unsymmetrischer thioehter |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5091313A (en) | 1988-08-05 | 1992-02-25 | Tanox Biosystems, Inc. | Antigenic epitopes of IgE present on B cell but not basophil surface |
| US5292867A (en) | 1988-11-16 | 1994-03-08 | Tanox Biosystems, Inc. | Chimeric monoclonal antibodies which bind to the extracellular segment of the membrane-bound domain of a human membrane-bound immunoglobulin |
| US5658897A (en) * | 1996-04-08 | 1997-08-19 | Allergan | Cyclopentane(ene) heptanoic or cyclopentane(ene) heptenoic acid, 2-hydrocarbyl phosphinyloxyalkyl or phosphonamidoalkyl as therapeutic agents |
| IL135438A (en) | 1997-10-03 | 2005-12-18 | Univ Temple | Pharmaceutical compositions containing styrl sulfones and some such novel styryl sulfone compounds with anticancer activity |
| US6548553B2 (en) | 1997-10-03 | 2003-04-15 | Temple University-Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| JP2002533322A (ja) * | 1998-12-22 | 2002-10-08 | エフ．ホフマン−ラ ロシュ アーゲー | ヒドロキサム酸スルホンアミド |
| US6201154B1 (en) | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| US6762207B1 (en) | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| AU774738B2 (en) * | 1999-04-02 | 2004-07-08 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| US6117364A (en) | 1999-05-27 | 2000-09-12 | Nalco/Exxon Energy Chemicals, L.P. | Acid corrosion inhibitor |
| US6656968B1 (en) | 1999-06-16 | 2003-12-02 | Temple University - Of The Commonwealth System Of Higher Education | (Z)-styryl acetoxyphenyl sulfides as cyclooxygenase inhibitors |
| CA2377153A1 (en) | 1999-06-16 | 2000-12-21 | Temple University - Of The Commonwealth System Of Higher Education | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
| WO2001023824A1 (en) | 1999-09-27 | 2001-04-05 | Vladimir Georgiev Peev | Striker trigger mechanism for automatic and semi-automatic firearms |
| US6767926B1 (en) * | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| US6486210B2 (en) | 2000-04-14 | 2002-11-26 | Temple University—Of the Commonwealth System of Higher Education | Substituted styryl benzylsulfones for treating proliferative disorders |
| US6541475B2 (en) | 2000-04-14 | 2003-04-01 | Temple University - Of The Commonwealth System Of Higher Education | α, β-unsaturated sulfones for treating proliferative disorders |
| ATE310724T1 (de) * | 2000-09-19 | 2005-12-15 | Taiho Pharmaceutical Co Ltd | Zusammensetzungen und verfahren zur verwendung achirale analoge von cc1065 und den duocarmycinen |
| JP2004510761A (ja) | 2000-10-05 | 2004-04-08 | テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション | 増殖性疾病を治療するための置換（ｅ）−スチリルベンジルスルホン |
| CA2439256A1 (en) | 2001-02-27 | 2002-09-06 | Temple University - Of The Commonwealth System Of Higher Education | (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| WO2002067865A2 (en) * | 2001-02-28 | 2002-09-06 | Temple University Of The Commonwealth System Of Higher Education | N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof |
| DE60228692D1 (de) | 2001-02-28 | 2008-10-16 | Univ Temple | Verwendung von alpha, beta ungesättigten arylsulfonen zum schutz von zellen und geweben vor toxizität ionischer strahlung |
| DE10113027A1 (de) * | 2001-03-17 | 2002-09-19 | Wella Ag | 3-(2,5-Diaminophenyl)-acrylamid-Derivate und diese Verbindungen enthaltende Färbemittel |
| US7078407B2 (en) * | 2001-11-23 | 2006-07-18 | Korea Research Institute Of Chemical Technology | 4-hydroxycinnamamide derivatives as antioxidants and pharmaceutical compositions containing them |
| EP1487428B1 (en) | 2002-02-28 | 2011-09-21 | Temple University - Of The Commonwealth System of Higher Education | Amino-substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| IL163608A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Temple | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| WO2004037751A2 (en) * | 2002-08-29 | 2004-05-06 | Temple University - Of The Commonwealth System Of Higher Education | Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof |
| AU2004289281C1 (en) | 2003-11-14 | 2011-12-08 | Onconova Therapeutics, Inc. | Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders |
| AU2006216544B2 (en) * | 2005-02-25 | 2012-04-05 | Onconova Therapeutics, Inc. | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis |
-
2005
- 2005-03-15 EA EA200901236A patent/EA200901236A1/ru unknown
- 2005-03-15 KR KR1020067020674A patent/KR101274524B1/ko not_active Expired - Lifetime
- 2005-03-15 NZ NZ549962A patent/NZ549962A/en not_active IP Right Cessation
- 2005-03-15 EP EP16190952.8A patent/EP3138832A1/en not_active Withdrawn
- 2005-03-15 AU AU2005222947A patent/AU2005222947B2/en not_active Ceased
- 2005-03-15 EP EP05736001.8A patent/EP1740530B8/en not_active Expired - Lifetime
- 2005-03-15 CA CA2559187A patent/CA2559187C/en not_active Expired - Lifetime
- 2005-03-15 ES ES05736001.8T patent/ES2609084T3/es not_active Expired - Lifetime
- 2005-03-15 US US10/592,604 patent/US7932242B2/en not_active Expired - Lifetime
- 2005-03-15 JP JP2007503993A patent/JP4918476B2/ja not_active Expired - Fee Related
- 2005-03-15 HU HUE05736001A patent/HUE030786T2/en unknown
- 2005-03-15 DK DK05736001.8T patent/DK1740530T3/da active
- 2005-03-15 WO PCT/US2005/008429 patent/WO2005089269A2/en not_active Ceased
- 2005-03-15 EA EA200601699A patent/EA012980B1/ru unknown
-
2006
- 2006-07-13 IL IL176836A patent/IL176836A/en active IP Right Grant
-
2011
- 2011-03-21 AU AU2011201245A patent/AU2011201245B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007529530A5 (enExample) | ||
| JP7685551B2 (ja) | Ｏ－置換セリン誘導体の製造方法 | |
| KR101514953B1 (ko) | 매크로사이클릭 화합물의 제조방법 | |
| EP1753775B1 (en) | Process for preparing acyclic hcv protease inhibitors | |
| CN113072497B (zh) | 蛋白酶抑制剂、其制备和用途 | |
| US8569453B2 (en) | Fluorene compound | |
| TWI302835B (en) | 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease | |
| CN1312817A (zh) | 截尾海兔肽15衍生物 | |
| CA2952541A1 (en) | Pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection | |
| WO2007102392A1 (ja) | Ｍｍｐ－１３選択的阻害剤 | |
| JPWO2006088248A1 (ja) | ポリオキシアルキレン誘導体 | |
| WO2008053913A1 (en) | Sulfonylurea derivative capable of selectively inhibiting mmp-13 | |
| TWI871182B (zh) | 用於fapi合成的中間體及其製備方法和應用 | |
| CN1168673A (zh) | 具有n-末端磺酰基或氨基磺酰基的新颖二肽对-脒基苄基酰胺 | |
| JP4393376B2 (ja) | フェニルシクロヘキシルプロパノールアミン誘導体、その製造法、およびその治療的適用 | |
| CN109134481B (zh) | 一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用 | |
| HU226688B1 (hu) | Szubsztituált 1,3-diaril-2-piridin-2-il-3-(piridin-2-il-amino)-propanol-származékok, eljárás az elõállításukra, alkalmazásuk és az ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
| JP2018501268A (ja) | チゾキサニドホスフェート及びアルカンスルホネート並びにその医薬用途 | |
| CN104788361A (zh) | 5-氮杂螺[2.4]庚烷-6-甲酸衍生物的合成方法 | |
| JPH07504417A (ja) | レトロウイルスプロテアーゼ拮抗薬 | |
| JPH082860B2 (ja) | ペプチド合成用新規カップリング剤 | |
| KR20200142529A (ko) | 치환된 피리디논-함유 트리사이클릭 화합물의 제조 방법 | |
| JP4800558B2 (ja) | 環状ペプチド誘導体 | |
| WO1999032459A1 (en) | Chymase inhibitors | |
| JPWO2002016404A1 (ja) | 環状ペプチド誘導体 |